Shanghai Sailiwei Biotechnology

Shanghai Sailiwei Biotechnology is a clinical-stage biopharmaceutical company specializing in the development of induced pluripotent stem cell (iPSC) derived therapies. The company focuses on treating central nervous system disorders, including spinal cord injury, Parkinson's disease, and ischemic stroke. Its lead candidate, SV-001, is a neural stem cell therapy derived from iPSCs currently undergoing clinical evaluation for spinal cord injury. Sailiwei leverages a proprietary platform for the large-scale production and differentiation of high-purity neural cells to address unmet medical needs in regenerative medicine. Based in Shanghai, the company is supported by prominent venture capital firms and maintains state-of-the-art R&D and manufacturing facilities.